Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant

Next Previous
Trial Profile

Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nifurtimox (Primary)
  • Indications Chagas disease
  • Focus Adverse reactions
  • Sponsors Bayer

Most Recent Events

  • 28 Jul 2025 Planned initiation date changed from 30 Jun 2025 to 31 Dec 2025.
  • 03 Jan 2025 Planned initiation date changed from 31 Dec 2024 to 30 Jun 2025.
  • 23 Jul 2024 Planned initiation date changed from 30 Jun 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top